Navigation Links
Treatment of common virus can reduce tumour growth
Date:9/27/2011

Researchers at Karolinska Institutet in Sweden have demonstrated for the first time that it is possible to inhibit the growth of brain tumours by treating the common Cytomegalovirus (CMV). The virus, which is found in a wide range of tumour types, offers a possible route towards controlling tumour growth and reducing the size of the tumour as a complement to conventional cytotoxin-based therapies.

The CMV is a common virus that is found in 70-75 per cent of the adult population. Normally it is dormant and goes unnoticed, but when a cancer develops in the body, the virus seems to control many of the mechanisms in the cancer cells. Brain tumours, breast cancer, colon cancer and prostate cancer are some of the cancer forms in which CMV may play a central role. By studying medullablastomas, the most common form of childhood brain tumour, researchers at Karolinska Institutet have been able to show for the first time the presence of CMV in these tumours and that treatment for CMV can reduce tumour growth.

"We show in this study that CMV is found in 92 per cent of tumours from medullablastoma patients," says Professor Cecilia Sderberg-Nauclr. "We also show in experimental systems that we can inhibit the growth of these tumours with antiviral drugs, which opens up a new potential therapeutic approach to certain tumours in the future."

Earlier studies have shown that many forms of tumour also have a higher expression of the COX-2 enzyme, which is not found in normal tissue but which plays a key part in inflammations and the development of cancer. As regards tumours, it has previously been shown that for unknown reasons COX-2 is induced in tumour cells; a phenomenon often associated with poor prognoses. Further, the knowledge that COX-2 inhibitors reduce the risk of cancer has led to their use in clinical studies for cancer prevention. CMV in turn, greatly and specifically stimulates the synthesis of COX-2 and is thus a possible control signal for tumour growth. COX-2 inhibitors also reduce the production of CMV. The researchers now show in their paper, which is published in the Journal of Clinical Investigation, that tumour growth decreases when CMV is inhibited.

"Our experiments on mice show that tumour growth declines by around 40 per cent when antiviral drugs or COX-2 inhibitors are used separately, and by no less than 72 per cent when used in combination," says Professor Sderberg-Nauclr, adding that this effect is achieved without using chemotherapy.

Since both the drugs used in the study, an NSAID that inhibits CMV replication and inflammation, and the antiviral Valcyte (Valganciclovir) for CMV infection, have relatively good adverse effect profiles, the researchers now see immediate opportunities for studying their impact on different forms of tumour. Antiviral drugs are also selective and largely affect infected cells.

"These are very promising and exciting results," says Professor Sderberg-Nauclr. "The virus infection isn't cured by the treatment, nor is the tumour, but the virus in the tumour decreases, which affects its growth. This therefore presents a new approach to treating tumours and could henceforth be used as a possible complementary therapy."


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. Women More Likely to Fail Treatment for Atrial Fibrillation
3. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. Nanofilm Introduces Clarity Defog It™ Anti Fog Treatment and EcoClens™ Eco-Friendly Lens Cleaner at Vision Expo East
6. Many veterans not getting enough treatment for PTSD
7. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
8. Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
9. Charging less for more effective treatments could reduce health care costs while improving health
10. Added Drug Aids MS Treatment
11. PTSD Treatment Still Lacking for Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Boulder, CO (PRWEB) , ... January 13, 2017 , ... ... Congress, a growing alliance of deans of colleges and schools of education across the ... public schools. , In a Declaration of Principles released today, 175 deans sounded the ...
(Date:1/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a new ... way to peace, health and eternal joy. Yisrayl says he has been accused of being ... that false accusations and persecution are nothing new in his world and says it has ...
(Date:1/13/2017)... , ... January 13, 2017 , ... One way to ... nationals can qualify if they can show their work is in the national interest. ... self-petition rather than having to be sponsored by an employer; and 2) the submission ...
(Date:1/13/2017)... ... 13, 2017 , ... U.S. News & World Report highly ... its 2017 Best Online Graduate Nursing Programs list released Jan. 10. The School ... graduate degree programs include a family nurse practitioner doctor of nursing practice (DNP), ...
(Date:1/13/2017)... ... 2017 , ... PrideStaff, a national, franchised staffing organization ... franchise by Entrepreneur. , The 38th annual Franchise 500® ranking was determined using ... success. All entrants were judged by financial strength and stability, growth rate and ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... Idaho , Jan. 12, 2017  Albertsons ... by Accreditation Commission for Health Care (ACHC) for ... largest national food and drug chain with this ... for pharmacy patients. Accreditation by ACHC ... national standards to facilitate a higher level of ...
(Date:1/13/2017)... 13, 2017  Biologics Prescribers Collaborative (BPC) ... (FDA) for issuing final guidance calling for ... policy is an important win for patients ... for pharmacovigilance, patient safety and transparency. ... to FDA, we remain concerned with "random" suffixes called ...
(Date:1/12/2017)... -- The global peripheral intravenous catheter market ... 3.8 Bn by 2016 end. Wide adoption of catheterization techniques in ... for PIVC. Rising disease prevalence will play a key role in ... likely to remain the largest market; Asia Pacific ... ...
Breaking Medicine Technology: